Zealand Pharma — August 2023
-
Zealand Pharma Announces Financial Results for the First Half of 2023 https://www.proinvestor.com/boards/114768
-
"Boehringer Ingelheim to move into Phase 3 trials with GCGR/GLP-1R dual agonist survodutide (BI456906) in obesity following positive Phase 2 data".
-
""We look forward to an eventful second half of the year as well, which we expect among other events will include the regulatory submission to the FDA for glepaglutide in SBS, a potential partnership agreement for dasiglucagon in CHI, and initiation by Boehringer Ingelheim of the Phase 3 program with survodutide in obesity."
-
Zealand Q2: Boehringer på vej i fase 3 med vægttabsmiddel https://www.proinvestor.com/investornyt/1035976/zealand-q2-boehringer-pa-vej-i-fase-3-med-vaegttabsmiddel
-
YPE 20.52..Jeg skriver som altid om kursbevægelser og handelsmønstre. Det være sig dem som kan aflæses her og nu - og dem som potentielt kan udspilles ved en bestemt begivenhed. F.eks. ved regnskabsaflæggelse. Alt det fundamentale lader jeg jer andre om.
-
Mornings
-
Spørgsmål til Q&A er meget velkommen.
-
nice rebound
-
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity - https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/obesity/survodutide-phase-iii-study-weight-loss
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind